Quick Answer
Nautilus Biotechnology, Inc. reported Stockholders Equity of $156.97 million for fiscal year 2025.
Nautilus Biotechnology, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $156.97M | -24.8% |
| 2024 | $208.73M | -21.3% |
| 2023 | $265.35M | -15.7% |
| 2022 | $314.92M | -13.4% |
| 2021 | $363.58M | +1323.3% |
| 2020 | -$29.72M | — |
| 2020 | $0.00 | +100.0% |
| 2019 | -$14.51M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $169.14M | -24.3% | -6.6% |
| June 30, 2025 | $181.09M | -23.0% | -6.9% |
| March 31, 2025 | $194.44M | -22.1% | -6.8% |
| December 31, 2024 | $208.73M | -21.3% | -6.6% |
| September 30, 2024 | $223.43M | -19.4% | -5.0% |
| June 30, 2024 | $235.28M | -18.8% | -5.7% |
| March 31, 2024 | $249.49M | -17.9% | -6.0% |
| December 31, 2023 | $265.35M | -15.7% | -4.3% |
- Nautilus Biotechnology, Inc. showed a decrease of -24.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Nautilus Biotechnology, Inc.’s stockholders equity has grown by 1181.9% (from -$14.51 million to $156.97 million).
- The most recent figure is from Nautilus Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: